Published in Cell Death Dis on September 04, 2014
Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol (2015) 0.94
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther (2015) 0.89
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem (2009) 23.19
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol (2009) 2.97
SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem (2011) 2.74
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther (2011) 2.48
SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res (2011) 2.46
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A (2010) 1.85
MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem (2006) 1.77
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.70
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer (2010) 1.63
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal (2012) 1.51
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (2007) 1.50
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol (2001) 1.46
Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene (2010) 1.46
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood (2009) 1.45
Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol (2000) 1.44
Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis (2011) 1.38
Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem (1999) 1.35
Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat Cell Biol (2001) 1.34
ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene (1997) 1.28
DNA methylation silences miR-132 in prostate cancer. Oncogene (2012) 1.27
Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem (2001) 1.27
p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep (2011) 1.25
The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol (2012) 1.25
Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res (2006) 1.20
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer (2011) 1.20
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett (2008) 1.17
MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res (2011) 1.16
Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer (2011) 1.15
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res (2010) 1.11
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem (2007) 1.08
miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun (2012) 1.08
Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res (2012) 1.07
Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol Cell Biochem (2010) 1.04
Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene (2002) 1.01
Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem (2012) 0.95
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene (1999) 0.94
A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem (1999) 0.93
Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem (2004) 0.93
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther (2010) 0.90
Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One (2011) 0.89
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs (2012) 0.86
Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Sci (2011) 0.86
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer (2012) 0.86
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology (2008) 0.84
Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation. Cancer Biol Ther (2011) 0.83
Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res (2012) 0.83
Role of Bruton's tyrosine kinase in macrophage apoptosis. Apoptosis (2011) 0.80
A protein kinase assay system for both acidic and basic peptides. Anal Biochem (1996) 0.79